Fig. 5From: The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systemsDiagnostic journey maps in 2 high-cost cystic fibrosis patients. BDP MDI beclomethasone dipropionate metered dose inhaler, CC complication/comorbidity, ICU intensive care unit, PERT pancreatic enzyme replacement therapyBack to article page